Comparing the current results to its competitors, Briacell Therapeutics reported Revenue decrease in the 3 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 12.41 %, recorded in the same quarter.
Briacell Therapeutics Corp , slower than the average decrease reported by the company's competitors of -40.05 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -40.05 %
Briacell Therapeutics 's Comment on Competition and Industry Peers
The cancer immunotherapy market includes large and medium-sized companies with approved products such as bispecific antibodies, CAR-T cells, and checkpoint inhibitors, as well as companies engaged in clinical development. Key competitors include Bristol-Myers Squibb Company, Merck & Co., Inc., Genentech, Inc. (a subsidiary of Roche Holding AG), AstraZeneca PLC, Celgene Corporation, Johnson & Johnson/Janssen Pharmaceuticals, Amgen, Novartis, and Acerta Pharmaceuticals. These companies generally possess greater financial, technical, and human resources, more regulatory approval experience, and stronger marketing and sales capabilities. Smaller or early-stage companies may also be significant competitors, particularly through collaborations with larger firms. Competition extends to recruiting qualified personnel and securing clinical trial resources. Products compete based on efficacy, safety, price, and reimbursement availability, with commercial opportunities potentially diminished if competitors develop superior products.
May 30, 2024
The fight against advanced metastatic breast cancer has taken a significant leap forward as BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), an innovative clinical-stage biotechnology company specializing in novel immunotherapies, commences patient enrollment in a pioneering Phase 1/2 clinical study. This trial seeks to evaluate the safety and efficacy of Bria-OTS, BriaCell s next-generation personalized off-the-shelf immunotherapy, when administered as a monotherapy and in combination with the PD-1 inhibitor tislelizumab. Study Overview Bria-OTS, an advanced personalized off-the-shelf immunotherapy, represents a groundbreaking approach that aims to revolutionize cancer care by using the body s ...
Publicly Traded Peers of Briacell Therapeutics Corp
Xbiotech Inc Share Performance
-1.36%
Over The Past 5 Days
Xbiotech Inc
Profile
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Sources:
Briacell Therapeutics Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Briacell Therapeutics Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
